Restricted accessReview articleFirst published online 2010-07
Successful Reduction of Surgeries Secondary to Arterial Access Site Complications: A Retrospective Review at a Single Center with an Extravascular Closure Device
Background: Access site complications requiring emergent surgery following femoral catheterization expose patients to additional morbidities and mortality. We observed a significant decrease in such surgeries after the Mynx device was introduced. Methods: A retrospective review of surgeries performed as a complication of 6F & 7F femoral cardiac and peripheral catheterization was done. Rates of surgeries among 3 closure methods were compared during the study period July 2006 to July 2008 (Mynx, AngioSeal, and manual/mechanical compression). Results: Of 11 006 6F &7F transfemoral catheterization procedures, 26 (0.24%) surgeries secondary to access complications resulted. Surgeries were done in 14 (0.61%) AngioSeal patients, 10 (0.19%) manual/mechanical compression, and 2 (0.06%) Mynx patients (P < .0001 vs AngioSeal, P = .14 vs compression). Conclusions: Significant reduction in surgeries was seen in the Mynx vs Angioseal patients, no difference was noted in compression subset. Further analysis is warranted to prospectively evaluate these findings.
Applegate RJ , Sacrinty MT, Kutcher MA, et al. Trends in vascular complications after diagnostic cardiac catheterization and percutaneous coronary intervention via the femoral artery, 1998 to 2007. JACC Cardiovasc Interv . 2008;1(3):317-326.
2.
Doyle BJ, Ting HH, Bell MR, et al. Major femoral bleeding complications after percutaneous coronary intervention: incidence, predictors, and impact on long-term survival among 17,901 patients treated at the Mayo Clinic from 1994 to 2005. JACC Cardiovasc Interv.2008;1(2):202-209.
3.
Feit F., Voeltz MD, Attubato MJ, et al. Predictors and impact of major hemorrhage on mortality following percutaneous coronary intervention from the REPLACE-2 Trial. Am J Cardiol. 2007; 100(9):1364-1369.
4.
Kim P., Dixon S., Eisenbrey AB, O’Malley B., Boura J., O’Neill W.Impact of acute blood loss anemia and red blood cell transfusion on mortality after percutaneous coronary intervention. Clin Cardiol. 2007;30(10 Suppl 2):1135-1143.
5.
Kinnaird TD, Stabile E., Mintz GS, et al. Incidence, predictors, and prognostic implications of bleeding and blood transfusion following percutaneous coronary interventions. Am J Cardiol. 2003;92(8):930-935.
6.
Moscucci M., Fox KA, Cannon CP, et al. Predictors of major bleeding in acute coronary syndromes: the Global Registry of Acute Coronary Events (GRACE). Eur Heart J. 2003;24(20):1815-1823.
7.
Ndrepepa G., Berger PB, Mehilli J., et al. Periprocedural bleeding and 1-year outcome after percutaneous coronary interventions: appropriateness of including bleeding as a component of a quadruple end point. J Am Coll Cardiol. 2008;51(7):690-697.
8.
Stone GW, McLaurin BT, Cox DA, et al. Bivalirudin for patients with acute coronary syndromes. N Engl J Med. 2006;355(21): 2203-2216.
9.
Yatskar L., Selzer F., Feit F., et al. Access site hematoma requiring blood transfusion predicts mortality in patients undergoing percutaneous coronary intervention: data from the National Heart, Lung, and Blood Institute Dynamic Registry. Catheter Cardiovasc Interv. 2007;69(7):961-966.
10.
Doyle BJ, Rihal CS, Gastineau DA, Holmes DR Jr.Bleeding, blood transfusion, and increased mortality after percutaneous coronary intervention: implications for contemporary practice. J Am Coll Cardiol. 2009;53(22):2019-2027.
11.
Koreny M., Riedmuller E., Nikfardjam M., Siostrzonek P., Mullner M.Arterial puncture closing devices compared with standard manual compression after cardiac catheterization: systematic review and meta-analysis. JAMA. 2004;291(3):350-357.
12.
Nikolsky E. , Mehran R., Halkin A., et al. Vascular complications associated with arteriotomy closure devices in patients undergoing percutaneous coronary procedures: a meta-analysis. J Am Coll Cardiol. 2004;44(6):1200-1209.
13.
Dauerman HL , Applegate RJ, Cohen DJVascular closure devices: the second decade . J Am Coll Cardiol. 2007;50(17): 1617-1626.
14.
Amin FR, Yousufuddin M., Stables R., et al. Femoral haemostasis after transcatheter therapeutic intervention: a prospective randomized study of the angio-seal device vs the femostop device . Int J Cardiol. 2000;76(2-3):235-240.
15.
Applegate RJ , Grabarczyk MA, Little WC, et al. Vascular closure devices in patients treated with anticoagulation and IIb/IIIa receptor inhibitors during percutaneous revascularization. J Am Coll Cardiol. 2002 ;40(1):78-83.
16.
Carere RG, Webb JG, Buller CE, et al. Suture closure of femoral arterial puncture sites after coronary angioplasty followed by same-day discharge. Am Heart J. 2000;139(1 Pt 1):52-58.
17.
Gerckens U., Cattelaens N., Lampe EG, Grube E.Management of arterial puncture site after catheterization procedures: evaluating a suture-mediated closure device. Am J Cardiol. 1999;83(12): 1658-1663.
18.
Meyerson SL, Feldman T., Desai TR, Leef J., Schwartz LB, McKinsey JFAngiographic access site complications in the era of arterial closure devices . Vasc Endovascular Surg. 2002; 36(2):137-144.
19.
Tavris DR, Gallauresi BA, Lin B., et al. Risk of local adverse events following cardiac catheterization by hemostasis device use and gender. J Invasive Cardiol. 2004;16(9):459-464.
20.
Wetter DR, Rickli H., von Smekal A., Amann FW. Early sheath removal after coronary artery interventions with use of a suture-mediated closure device: clinical outcome and results of Doppler US evaluation. J Vasc Interv Radiol. 2000;11(8):1033-1037.
21.
Assali AR, Sdringola S., Moustapha A., et al. Outcome of access site in patients treated with platelet glycoprotein IIb/IIIa inhibitors in the era of closure devices. Catheter Cardiovasc Interv. 2003;58(1):1-5.
22.
Carey D., Martin JR, Moore CA, Valentine MC, Nygaard TWComplications of femoral artery closure devices. Catheter Cardiovasc Interv.2001;52(1):3-7; ;discussion 8.
23.
Arora N., Matheny ME, Sepke C., Resnic FSA propensity analysis of the risk of vascular complications after cardiac catheterization procedures with the use of vascular closure devices. Am Heart J. 2007;153(4):606-611.
24.
Chevalier B. , Lancelin B., Koning R., et al. Effect of a closure device on complication rates in high-local-risk patients: results of a randomized multicenter trial . Catheter Cardiovasc Interv. 2003;58(3):285-291.
25.
Cremonesi A. , Castriota F., Tarantino F., et al. Femoral arterial hemostasis using the angio-seal feminine system after coronary and vascular percutaneous angioplasty and stenting. J Invasive Cardiol. 1998;10(8):464-469.
26.
Gemmete JJ, Dasika N., Forauer AR, Cho K., Williams DMSuccessful angioplasty of a superficial femoral artery stenosis caused by a suture-mediated closure device. Cardiovasc Intervent Radiol . 2003;26(4):410-412.
27.
Jang JJ, Kim M., Gray B., Bacharach JM, Olin JWClaudication secondary to Perclose use after percutaneous procedures. Catheter Cardiovasc Interv. 2006;67(5):687-695.
28.
Stock U., Flach P., Gross M., Meyhofer J., Albes J., Butter C.Intravascular misplacement of an extravascular closure system: StarClose. J Interv Cardiol. 2006;19(2):170-172.
29.
Warren BS, Warren SG, Miller SDPredictors of complications and learning curve using the Angio-Seal closure device following interventional and diagnostic catheterization. Catheter Cardiovasc Interv. 1999;48(2):162-166.
30.
Scheinert D. , Sievert H., Turco MA, et al. The safety and efficacy of an extravascular, water-soluble sealant for vascular closure: initial clinical results for Mynx . Catheter Cardiovasc Interv. 2007;70(5):627-633.
31.
Piper WD, Malenka DJ, Ryan TJ Jr, et al. Predicting vascular complications in percutaneous coronary interventions . Am Heart J. 2003;145(6):1022-1029.
32.
Tavris DR, Dey S., Albrecht-Gallauresi B., et al. Risk of local adverse events following cardiac catheterization by hemostasis device use-phase II. J Invasive Cardiol. 2005;17(12): 644-650.
